The Week Ahead: Hom...
Health Care: Drugs
Apricus Biosciences Inc. (APRI: NASDAQ)
$3.24 0.22 | 7.28%
05/17/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 8.42M | 4.10M | 4.97M | 2.97M |
| Cost of Sales | 12.57M | 1.60M | 4.40M | 128.36K |
| Gross Operating Profit | -4.15M | 2.50M | 577.01K | 2.85M |
| Selling, General, and Administrative Expenses | 15.38M | 11.46M | 10.15M | 4.20M |
| Research & Development | 5.38M | 5.82M | 2.11M | 1.88M |
| Operating Income before D & A (EBITDA) | -24.90M | -14.78M | -11.69M | -3.23M |
| Depreciation & Amortization | 240.00K | 639.47K | 9.72M | 28.74M |
| Interest Income | 0.00 | 13.73K | 28.02K | 25.29K |
| Other Income - Net | 175.00K | -2.33M | 715.08K | 10.20K |
| Special Income / Charges | 250.00K | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -24.72M | -17.74M | -20.66M | -32.52M |
| Interest Expense | 325.00K | 376.92K | 8.85M | 28.70M |
| Pre-Tax Income | -25.04M | -18.12M | -29.51M | -61.22M |
| Income Taxes | 516.00K | 0.00 | 0.00 | -437.79K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -25.56M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | -6.21M | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -31.77M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -31.77M | -18.12M | -29.51M | -32.04M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-25.81M | 0.00 | 0.00 | 585.38K |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -25.56M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.93 | -0.90 | -2.49 | -5.40 |
| Basic EPS from Discontinued Ops. | -0.23 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.16 | -0.90 | -2.49 | -5.40 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.16 | -0.90 | -2.49 | -5.40 |
| Basic Normalized Net Income/Share | -0.94 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.93 | -0.90 | -2.49 | -5.40 |
| EPS fr Discontinued Ops | -0.23 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.16 | -0.90 | -2.49 | -5.40 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.16 | -0.90 | -2.49 | -5.40 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.94 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with APRI
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
Latest APRI Headlines from TheStreet
- Apricus Biosciences Provides First Quarter 2013 Corporate Update 05.10.13 | 08:05 am
- Apricus Biosciences Announces First Quarter 2013 Financial Results Conference Call 05.07.13 | 02:05 pm
- Apricus Biosciences Announces Poster Presentation Of Vitaros(R) Data In Men Previously Unresponsive To PDE-5 Inhibitors At American Urological Association Annual Meeting 05.07.13 | 11:05 am
- Apricus Biosciences To Present At 2013 BIO International Convention 04.18.13 | 07:04 am
- Apricus Biosciences Announces Sale Of Non-Core Assets 04.01.13 | 04:04 pm
- Apricus Biosciences Provides Corporate Update; Files Annual Report For Quarter And Year Ended December 31, 2012 03.18.13 | 11:03 am
- Apricus Biosciences Appoints Richard W. Pascoe As Chief Executive Officer 03.18.13 | 11:03 am
- Apricus Biosciences Announces 2012 Year End Financial Results Conference Call 03.14.13 | 09:03 am
- Apricus Biosciences Announces Ceasing Of Financing Of French Subsidiaries 03.14.13 | 08:03 am
- Apricus Biosciences To Present At The 25th Annual ROTH Conference 03.13.13 | 04:03 pm
Press Releases for APRI
- Apricus Biosciences, Inc. (APRI) Transforms From Development Company To Income Generating! - PR Newswire 03.14.12 | 09:03 am
- Apricus Biosciences To File For Market Authorization To Sell Vitaros® For Erectile Dysfunction In Latin America - PR Newswire 08.08.11 | 07:08 pm
- Apricus Biosciences Launches Educational Video Series Focused On Its Newly Approved Erectile Dysfunction Drug, Vitaros® - Business Wire 12.06.10 | 09:12 am
- Apricus Biosciences Appoints Manufacturer For Vitaros®, Its Newly Approved Drug To Treat Erectile Dysfunction In Canada - Business Wire 12.01.10 | 10:12 am
- Apricus Biosciences Announces New NexACT® Transbuccal Delivery Data Published In The International Journal Of Pharmaceutics - Business Wire 11.29.10 | 10:11 am
- Apricus Biosciences Files Phase 3 Registration Protocol For PrevOnco™ For Special Protocol Assessment Consideration By The FDA - Business Wire 11.22.10 | 10:11 am
- Apricus Bio Announces Pre-Clinical Data Showing Significant Improvement In Solubility And Absorption Of NexACT®-Based Small Molecule Drugs Selected From The Biopharmaceutics Classification System - Business Wire 11.19.10 | 10:11 am
- Apricus Biosciences’ CEO Bassam Damaj, Ph.D., Interviewed By The Financial Network CDTV.net - Business Wire 11.17.10 | 10:11 am
- Apricus Biosciences Receives Canadian Approval For Vitaros® As First Line Therapy For Erectile Dysfunction - Business Wire 11.15.10 | 12:11 pm
- Apricus Biosciences Announces 2010 Third Quarter Financial Results Conference Call - Business Wire 11.10.10 | 10:11 am
Partner Headlines for APRI
- Smart Stocks Watch: Apricus Biosciences - Seeking Alpha 09.21.12 | 09:09 am
- Apricus, Takeda Ink Marketing Deal - Analyst Blog - NASDAQ 09.14.12 | 10:09 pm
- Apricus, Takeda Ink Marketing Deal - Analyst Blog - Zacks 09.14.12 | 06:09 pm
- Tesaro Initiated at OUTPERFORM and 2 Initiated Shares on the Move - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- REVEALED: New Stock Analyst Coverage to Evaluate - Wall St. Cheat Sheet 06.14.12 | 03:06 am
- Apricus Biosciences Strengthens Vitaros and Nexact Patent Estate With Two New Patent Allowances - Benzinga 05.25.12 | 01:05 pm
- Apricus Biosciences Granted Regulatory Meeting With FDA for Femprox(R) for the Treatment of Female Sexual Arousal Disorder - Benzinga 05.21.12 | 09:05 am
- Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for the Treatment of Onychomycosis - Benzinga 05.11.12 | 09:05 am
- Apricus Biosciences; Vitaros Has Great Potential - Seeking Alpha 04.22.12 | 09:04 am
- Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa in the Middle East and the Gulf - Benzinga 01.10.12 | 09:01 am
